Abliva AB announced that the Board of Directors, in agreement with Dr. Erik Kinnman, the current CEO, has appointed Dr. Ellen K. Donnelly, Ph.D. as the company's new CEO to lead Abliva's development into a commercial biopharmaceutical company. Dr. Donnelly succeeds Dr. Erik Kinnman, around February 3rd. Most recently, Ellen was CEO of the Division of Epigenetics at Juvenescence and CEO for its subsidiary company, Souvien Therapeutics.